Background: Splenic marginal zone lymphomas (MZL) in dogs arise from the marginal zone of B-cell follicles and can progress slowly.Objectives: To describe clinical features, treatment, and outcome of dogs with splenic MZL.Animals: Five dogs with naturally occurring MZL.Methods: Clinical, laboratory, and follow-up data were retrospectively reviewed. Diagnosis was based on clinical, histopathological, and immunophenotypic features.Results: All dogs had stage IV disease; among them, 2 were symptomatic (substage "b") because of splenic rupture. Four dogs underwent splenectomy and adjuvant doxorubicin, and 1 dog underwent surgery only. Three out of the 4 dogs treated with surgery and chemotherapy died of causes unrelated to lymphoma, after 760, 939, and 1,825 days, whereas the remaining dog was alive and in complete remission after 445 days. The dog not receiving any adjuvant treatment had recurrence of the tumor after 180 days.Conclusions and Clinical Importance: Splenic MZL appears indolent and can benefit from splenectomy, with or without systemic chemotherapy. Copyright

D. Stefanello, P. Valenti, E. Zini, S. Comazzi, M.E Gelain, P. Roccabianca, et al. (2011). Splenic marginal zone lymphoma in 5 dogs (2001-2008). JOURNAL OF VETERINARY INTERNAL MEDICINE, 25(1), 90-93 [10.1111/j.1939-1676.2010.0639.x].

Splenic marginal zone lymphoma in 5 dogs (2001-2008)

AVALLONE, GIANCARLO;L. Marconato
2011

Abstract

Background: Splenic marginal zone lymphomas (MZL) in dogs arise from the marginal zone of B-cell follicles and can progress slowly.Objectives: To describe clinical features, treatment, and outcome of dogs with splenic MZL.Animals: Five dogs with naturally occurring MZL.Methods: Clinical, laboratory, and follow-up data were retrospectively reviewed. Diagnosis was based on clinical, histopathological, and immunophenotypic features.Results: All dogs had stage IV disease; among them, 2 were symptomatic (substage "b") because of splenic rupture. Four dogs underwent splenectomy and adjuvant doxorubicin, and 1 dog underwent surgery only. Three out of the 4 dogs treated with surgery and chemotherapy died of causes unrelated to lymphoma, after 760, 939, and 1,825 days, whereas the remaining dog was alive and in complete remission after 445 days. The dog not receiving any adjuvant treatment had recurrence of the tumor after 180 days.Conclusions and Clinical Importance: Splenic MZL appears indolent and can benefit from splenectomy, with or without systemic chemotherapy. Copyright
2011
D. Stefanello, P. Valenti, E. Zini, S. Comazzi, M.E Gelain, P. Roccabianca, et al. (2011). Splenic marginal zone lymphoma in 5 dogs (2001-2008). JOURNAL OF VETERINARY INTERNAL MEDICINE, 25(1), 90-93 [10.1111/j.1939-1676.2010.0639.x].
D. Stefanello; P. Valenti; E. Zini; S. Comazzi; M.E Gelain; P. Roccabianca; G. Avallone; M. Caniatti; L. Marconato
File in questo prodotto:
File Dimensione Formato  
Splenic Marginal Zone Lymphoma in 5 Dogs (2001–2008).pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 1.15 MB
Formato Adobe PDF
1.15 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/547122
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 25
social impact